Uveitis Therapeutics in Asia-Pacific Market Growing rapidly due to Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs

Uveitis Therapeutics
Get an extensive global Uveitis Therapeutics market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry.

HTF Market Report released a new research document of 91 pages on industry titled as ‘Uveitis Therapeutics in Asia-Pacific Markets to 2023 – Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market‘ with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions and important players/vendors. The report will help you gain market insights, future trends and growth prospects for forecast period of 2023.

Request a sample report @ https://www.htfmarketreport.com/sample-report/1000224-uveitis-therapeutics-in-asia-pacific-market

Uveitis refers to inflammation of the uvea, the middle vascular coat of the eye, comprising the iris, ciliary body, and choroid. It may also involve other adjacent tissues of the eye. Uveitis occurs at any age, but it most commonly affects individuals between 20 and 59 years of age. However, this trend is changing; the percentage of elderly uveitis patients has been increasing in recent years. Uveitis represents a major cause of ocular morbidity worldwide and often results in complications such as cataracts, glaucoma, ocular hypertension, macular issues, and retinal detachment.

It is a leading cause of blindness in both developed and developing countries and is the fifth most common cause of vision loss in the developed world. The uveitis market is characterized by a small selection of marketed drug options, consisting of corticosteroid therapies, immunosuppressive therapies and biologics. Historically, corticosteroid therapies have made up the bulk of the uveitis market.

Currently only one targeted therapy is available in the Asia-Pacific uveitis market, which is AbbVie’s Humira (adalimumab). The late-stage uveitis pipeline is composed of Santen’s Opsiria and Clearside Biomedical’s CLS-TA, which are expected to be highly lucrative and address some of the unmet needs.

These new drugs will expand the options available to treat uveitis patients and contribute to overall market growth by offering novel treatment mechanisms, including new drug delivery routes and novel, non-corticosteroid drug molecules.

Get Customization in the Report, Enquire Now @ https://www.htfmarketreport.com/enquiry-before-buy/1000224-uveitis-therapeutics-in-asia-pacific-market

Scope

– The Asia-Pacific uveitis market will be valued at $405.5m in 2023, growing from $179m in 2016, at a compound annual growth rate of 12.4%.

– What are the key factors driving the Asia-Pacific uveitis treatment market?

– How will targeted therapies such as Humira contribute to growth?

– Do branded therapies show continuous growth, and are they facing competition from generics?

– How will branded therapies be affected by upcoming pipeline therapies?

– Corticosteroid therapies dominate the uveitis market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs?

– What are the common targets and mechanisms of action of pipeline therapies?

– What are the commercial prospects for the most promising late-stage products?

– Various drivers and barriers will influence the market over the forecast period.

– What are the barriers that will limit the uptake of premium-priced therapies in the assessed countries?

– Which factors are most likely to drive the market in these countries?

– What licensing and co-development deals have occurred within this therapy area since 2006?

Reasons to buy

– Understand the current clinical and commercial landscape through a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, epidemiology, prognosis and treatment.

– Visualize the composition of the uveitis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.

– Analyze the uveitis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.

– Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.

– Predict uveitis market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.

– Identify commercial opportunities in the uveitis deals landscape by analyzing trends in licensing and co-development deals.

Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=1000224

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 9

2.1 Disease Introduction 9

2.2 Epidemiology 10

2.3 Symptoms 11

2.4 Etiology and Pathophysiology 11

2.4.1 Autoimmune uveitis 12

2.4.2 Non-autoimmune uveitis 12

2.5 Diagnosis 14

2.6 Prognosis 15

2.7 Treatment Options 16

2.7.1 Corticosteroids 17

2.7.2 Immunosuppressive Agents 18

2.7.3 Biologics 18

2.7.4 Adjuvant Therapy 19

3 Marketed Products 20

4 Pipeline Analysis 32

5 Clinical Trial Analysis 42….Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/1000224-uveitis-therapeutics-in-asia-pacific-market

It’s vital you keep your market knowledge up to date. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization accordingly.

About Author: 
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”. 

Media Contact
Company Name: HTF Market Intelligence Consulting Private Limited
Contact Person: Craig Francis
Email: Send Email
Phone: 2063171218
Address:Unit No. 429, Parsonage Road
City: Edison
State: New Jersey
Country: United States
Website: https://www.htfmarketreport.com/reports/1000224-uveitis-therapeutics-in-asia-pacific-market